A new study published in the journal of BMC Nephrology revealed rituximab to be an effective and safe steroid sparing medication in individuals with steroid dependent (SD)/frequent relapsing ...

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...

Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of ...

High-dose methotrexate (HD-MTX) with the modified Bonn protocol including intrathecal therapy is effective for patients less than 65 years old with primary central nervous system lymphoma (PCNSL), ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

A simple algorithm to recommend disease-modifying therapies may help reduce racial and ethnic inequalities in MS treatment, per a study.

Bradley Monk shares key insights and breakthroughs in gynaecologic oncology from ESGO 2025, shaping cancer care's future.

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...